Last reviewed · How we verify
MenACWY-CRM Vaccine
MenACWY-CRM Vaccine is a Conjugate vaccine Biologic drug developed by Novartis. It is currently in Phase 3 development for Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y.
MenACWY-CRM is a conjugate vaccine that stimulates the immune system to produce antibodies against meningococcal serogroups A, C, W, and Y by coupling polysaccharide antigens to a carrier protein.
MenACWY-CRM is a conjugate vaccine that stimulates the immune system to produce antibodies against meningococcal serogroups A, C, W, and Y by coupling polysaccharide antigens to a carrier protein. Used for Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y.
At a glance
| Generic name | MenACWY-CRM Vaccine |
|---|---|
| Sponsor | Novartis |
| Drug class | Conjugate vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
The vaccine contains purified capsular polysaccharides from Neisseria meningitidis serogroups A, C, W, and Y conjugated to CRM197 (a non-toxic diphtheria toxin variant), which enhances immunogenicity and T-cell dependent responses. This conjugation allows the vaccine to elicit both IgG antibodies and immunological memory, providing protection against invasive meningococcal disease caused by these four serogroups.
Approved indications
- Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y
Common side effects
- Injection site pain
- Injection site erythema
- Injection site swelling
- Myalgia
- Headache
- Fatigue
- Fever
Key clinical trials
- A Trial to Describe the Immunogenicity and Safety of 2 Doses of Bivalent rLP2086 (Trumenba) and a Pentavalent Meningococcal Vaccine in Healthy Subjects >=10 to <26 Years of Age. (PHASE3)
- Immunogenicity and Safety of Meningococcal ACWY Conjugate Vaccine in Healthy Children, Adolescents and Adults in Russia (PHASE3)
- MenABCWY Noninferiority Study in Healthy Participants ≥10 to <26 Years of Age (PHASE3)
- Adolescent MenACWY Booster Study (PHASE4)
- Study to Assess the Safety and Immunogenicity of a Single Dose of GlaxoSmithKline's (GSK) Meningococcal MenACWY-CRM Vaccine (Menveo), Administered to Subjects 15 Through 55 Years of Age, Approximately 4-6 Years After Primary ACWY Vaccination (PHASE3)
- Meningococcal Quadrivalent CRM-197 Conjugate Vaccine Infant Study
- Immunogenicity, Safety and 1 Year Persistence of Antibodies After Either One or Two Doses of Meningococcal ACWY Conjugate Vaccine in Healthy Children 2 Through 10 Years of Age. (PHASE3)
- Safety and Immunogenicity of Meningococcal ACWY Conjugate Versus Polysaccharide Vaccine in Children 2 to 10 Years of Age (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MenACWY-CRM Vaccine CI brief — competitive landscape report
- MenACWY-CRM Vaccine updates RSS · CI watch RSS
- Novartis portfolio CI
Frequently asked questions about MenACWY-CRM Vaccine
What is MenACWY-CRM Vaccine?
How does MenACWY-CRM Vaccine work?
What is MenACWY-CRM Vaccine used for?
Who makes MenACWY-CRM Vaccine?
What drug class is MenACWY-CRM Vaccine in?
What development phase is MenACWY-CRM Vaccine in?
What are the side effects of MenACWY-CRM Vaccine?
Related
- Drug class: All Conjugate vaccine drugs
- Manufacturer: Novartis — full pipeline
- Therapeutic area: All drugs in Immunology / Infectious Disease
- Indication: Drugs for Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y
- Compare: MenACWY-CRM Vaccine vs similar drugs
- Pricing: MenACWY-CRM Vaccine cost, discount & access